Antiangiogenic therapy for high-grade glioma-Reference-Cited by-同舟云学术

Antiangiogenic therapy for high-grade glioma

Published:2014-09-22 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Khasraw Mustafa¹,Ameratunga Malaka S²,Grant Robin³,Wheeler Helen⁴,Pavlakis Nick⁴

Affiliation:

1. NHMRC Clinical Trials Centre, University of Sydney; University of Sydney Sydney Australia

2. Barwon Health; Andrew Love Cancer Centre; 70 Swanston Street Geelong Victoria Australia 3220

3. Western General Hospital; Edinburgh Centre for Neuro-Oncology (ECNO); Crewe Road Edinburgh Scotland UK EH4 2XU

4. Royal North Shore Hospital; Department of Medical Oncology; Pacific Highway Sydney NSW Australia 2065

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD008218.pub3/fullpdf

Reference42 articles.

1. Batchelor TT Mulholland P Neyns B Nabors LB Campone M Wick A Phase III randomised trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma Journal of Clinical Oncology 3212 8

2. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study;Taal;Journal of Clinical Oncology,2013

3. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study;Stupp;Journal of Clinical Oncology,2013

4. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;Chinot;New England Journal of Medicine,2014

5. Nabors LB Fink KL Mikkelsen T Grujicic D Tarnawski R Nam DH A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter: initial report of the CORE study 18th Annual SNO Scientific Meeting: Conference Proceedings 2013 80

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma;World Neurosurgery;2023-11

2. Prognostic risk of immune-associated signature in the microenvironment of brain gliomas;Frontiers in Genetics;2023-10-06

3. Scale-free correlations and potential criticality in weakly ordered populations of brain cancer cells;Science Advances;2023-06-30

4. CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review;Current Issues in Molecular Biology;2023-06-22

5. Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma;Frontiers in Neurology;2023-05-25